Transaction DateRecipientSharesTypePriceValue
19th November 2020William Jl Rieflin10,000Open or private purchase$16.22$162,200.00
12th October 2020Jin Long Chen25,000Open or private sale$17.02$425,500.00
22nd September 2020Peter Svennilson608,000Open or private sale$30.85$18,756,800.00
2nd September 2020Group L P Column27,595Open or private purchase$17.67$487,603.65
1st September 2020Jin Long Chen7,613Open or private sale$18.32$139,470.16
1st September 2020Group L P Column36,494Open or private purchase$17.64$643,754.16
1st September 2020Jin Long Chen17,387Open or private sale$17.62$306,358.94
28th August 2020Group L P Column26,135Open or private purchase$17.89$467,555.15
27th August 2020Group L P Column36,359Open or private purchase$17.79$646,826.61
25th August 2020Group L P Column100Open or private purchase$18.00$1,800.00
Ngm Biopharmaceuticals
Ngm Biopharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity and oncology.


Ticker: NGM
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1426332
Employees:
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals